Intra-Cellular Therapies Inc.

ITCI Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
ITCI Income Statement
ITCI Balance Sheet
ITCI Cash Flow
Congress Trading

Recent trades of ITCI by members of U.S. Congress

Politician Type Traded
Josh Gottheimer House / D Sale $1,001 - $15,000 Jun. 21, 2024
Josh Gottheimer House / D Purchase $1,001 - $15,000 Dec. 21, 2021
Roger Marshall House / R Purchase $1,001 - $15,000 May. 01, 2017
ITCI Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
ITCI Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
ITCI Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by ITCI's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $50,000 Oct 21, 2024 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
  • $50,000 Jul 22, 2024 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
  • $70,000 Apr 22, 2024 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
  • $40,000 Jan 22, 2024 Issue: Health Issues
  • $10,000 Oct 19, 2023 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
  • $40,000 Jul 17, 2023 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
  • $80,000 Jun 21, 2023 Issue: Medicare/Medicaid
  • $50,000 Jan 19, 2023 Issue: Health Issues Medicare/Medicaid
  • $15,000 Nov 21, 2022 Issue: Medicare/Medicaid Health Issues
  • $20,000 Oct 20, 2022 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
  • $10,000 Apr 20, 2022 Issue: Medicare/Medicaid Health Issues
  • $20,000 Feb 28, 2005 Issue: Budget/Appropriations
  • $20,000 Aug 20, 2004 Issue: Budget/Appropriations
Corporate Lobbying

Estimated quarterly lobbying spending

U.S. Patents

New patents grants

  • Patent Title: Process for preparing 1-(4-fluorophenyl)-4-((6br, 10as)-3-methyl-2,3,6b,9,10,10a-hexahydro-1h-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7h)-yl)butan-1-one Nov. 12, 2024
  • Patent Title: Pharmaceutical capsules comprising lumateperone mono-tosylate Oct. 29, 2024
  • Patent Title: Pharmaceutical compositions comprising 4-((6br,10as)-3-methyl2,3,6b,9,10,10a-hexahydro-1h-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin8(7h)-yl)-1-(4-((6br,10as)-3-methyl-2,3,6b,9,10,10a-hexahydro-1h-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7h)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders Oct. 22, 2024
  • Patent Title: Methods Sep. 17, 2024
  • Patent Title: Pharmaceutical capsule compositions comprising lumateperone mono-tosylate Aug. 27, 2024
  • Patent Title: Methods Jul. 02, 2024
  • Patent Title: Methods of treating acute depression and/or acute anxiety May. 14, 2024
  • Patent Title: Compounds and methods Apr. 16, 2024
  • Patent Title: Methods Apr. 16, 2024
  • Patent Title: Amorphous solid dispersions Jan. 16, 2024
  • Patent Title: Organic compounds Dec. 19, 2023
  • Patent Title: Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine a Dec. 12, 2023
  • Patent Title: Amorphous solid dispersions Nov. 28, 2023
  • Patent Title: Methods of treatment using pharmaceutical capsule compositions comprising lumateperone mono-tosylate Nov. 07, 2023
  • Patent Title: Transmucosal methods for treating psychiatric and neurological conditions Nov. 07, 2023
  • Patent Title: Organic compounds Oct. 03, 2023
  • Patent Title: Uses Sep. 19, 2023
  • Patent Title: 4-((6br,10as)-3-methyl-2,3,6b,9,10,10a-hexahydro-1h-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7h)-yl)-1-(4-((6br,10as)-3-methyl-2,3,6b,9,10,10a-hexahydro-1h-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7h)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders Sep. 12, 2023
  • Patent Title: Organic compounds Aug. 15, 2023
  • Patent Title: Pharmaceutical capsule compositions comprising lumateperone mono-tosylate Jul. 04, 2023
  • Patent Title: Pharmaceutical compositions comprising 4-(6br,10as)-3-methyl-2, 3, 6b, 9, 10, 10a-hexahydro-1h, 7h-pyrido[3′, 4′, 5] pyrolo[1,2,3-de] quinoxalin-8yl)-1-(4-fluorophenyl)-butane-1-one and methods of treating conditions of the central nervous system Jun. 20, 2023
  • Patent Title: Organic compounds Jan. 24, 2023
  • Patent Title: Uses Nov. 22, 2022
  • Patent Title: Organic compounds Nov. 08, 2022
  • Patent Title: Pde1 inhibitors for ophthalmic disorders Oct. 11, 2022
  • Patent Title: Substituted heterocycle fused gamma-carbolines synthesis Sep. 27, 2022
  • Patent Title: Salts and crystals Sep. 13, 2022
  • Patent Title: Organic compounds Aug. 30, 2022
  • Patent Title: Hydrochloric acid salt of (6br,10as)-3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1h-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxaline Aug. 09, 2022
  • Patent Title: Organic compounds Jul. 05, 2022
  • Patent Title: Amorphous solid dispersions May. 17, 2022
  • Patent Title: Amorphous solid dispersions Apr. 26, 2022
  • Patent Title: Uses Apr. 05, 2022
  • Patent Title: Methods and compositions for sleep disorders and other disorders Dec. 07, 2021
  • Patent Title: 4-((6br,10as)-3-methyl-2,3,6b,9,10,10a-hexahydro-1h-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7h)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms Nov. 23, 2021
  • Patent Title: Combinations of pde1 inhibitors and nep inhibitors Nov. 09, 2021
  • Patent Title: Compositions and methods Sep. 21, 2021
  • Patent Title: Organic compounds Aug. 24, 2021
  • Patent Title: Preparation of certain substituted 1h-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines and pharmaceutically acceptable salts thereof Jul. 20, 2021
  • Patent Title: Methods Jul. 06, 2021
  • Patent Title: Pharmaceutical capsule compositions comprising lumateperone mono-tosylate Jul. 06, 2021
  • Patent Title: Transmucosal methods for treating psychiatric and neurological conditions Jul. 06, 2021
  • Patent Title: Methods of treating bipolar disorder Jun. 08, 2021
  • Patent Title: Co-crystals of 1-(4-fluoro-phenyl)-4-((6br,1oas)-3-methyl-2,3,6b,9,10,10a-hexahydro-1h,7h- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide May. 25, 2021
  • Patent Title: Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders Mar. 30, 2021
  • Patent Title: Pharmaceutical compositions for sustained or delayed release Mar. 30, 2021
  • Patent Title: Methods of treating schizophrenia and depression Mar. 30, 2021
  • Patent Title: Organic compounds Feb. 02, 2021
  • Patent Title: Organic compounds Jan. 26, 2021
  • Patent Title: Pharmaceutical compositions comprising 4-(6br,10as)-3-methyl-2,3,6b,9,10,10a-hexahydro-1h, 7h-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)butan-1-one and methods of treating conditions of the central nervous system Nov. 24, 2020
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded from public contracts

WallStreetBets

Number of mentions of ITCI in WallStreetBets Daily Discussion

ITCI News

Recent insights relating to ITCI

CNBC Recommendations

Recent picks made for ITCI stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ITCI

ITCI Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view ITCI Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top